AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03386032
Drug: 0.05% Desonide
DrugBank: Desonide (DB01260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rx Steroid applied topically, twice daily, once in the morning and once in the evening, for 8 weeks to all atopic dermatitis lesions.~Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to whole body as body moisturizer, except atopic dermatitis lesions.
Trial: NCT03364348
Drug: Utomilumab
RxNorm normalized name: Utomilumab
DrugBank: Utomilumab (DB15113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03364348
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT03364348
Drug: Ado-Trastuzumab Emtansine
RxNorm normalized name: Ado-Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT04508452
Drug: Capecitabine-Oxaliplatin-Irinotecan-Bevacizumab Combination
RxNorm normalized name: Capecitabine
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: CAP 1,600 mg/sq.m /day (p.o. day1-10) D1-10; Oxaliplatin (OX): 68 mg/sq.m (d.i.v.) D1; Irinotecan (IRI):135 mg/sq.m (d.i.v.) D1; BEV: 5mg/kg (d.i.v.) D1; Administered every 2 weeks.
Trial: NCT00005993
Drug: aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00005993
Drug: filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04325698
Drug: PF-06439535 (CN)
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg, IV on day 1 of each 21 day cycle for up to 2 years, or until progression or unacceptable toxicity develops.
Trial: NCT00005993
Drug: recombinant human stem cell factor
RxNorm normalized name: antihemophilic factor, human recombinant
DrugBank: Antihemophilic factor, human recombinant (DB00025)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04325698
Drug: Bevacizumab-EU
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15 mg/kg, IV on day 1 of each 21 day cycle until disease progression, unacceptable toxicity or 25 weeks. At Week 25, the participants with clinical benefit will received PF-06439535 (CN) monotherapy for up to 2 years from randomization in this study
Trial: NCT04325698
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 175 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
Trial: NCT04325698
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC 5 (max=750mg) via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
Trial: NCT03813147
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT03813147
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intrathecally and IV
Trial: NCT03813147
Drug: Fludarabine Phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03813147
Drug: Pevonedistat
RxNorm normalized name: Pevonedistat
DrugBank: Pevonedistat (DB11759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04206176
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 45mg twice daily per oral administration
Trial: NCT00962091
Drug: Alisertib
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib OS Alisertib PIC Alisertib PIC
Trial: NCT02631460
Drug: pemetrexed 500 mg/m2
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: d1, every 3 weeks
Trial: NCT02631460
Drug: carboplatin AUC=5
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: d1, every 3 weeks
Trial: NCT03104426
Drug: Darbepoetin Alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa dosage 10microg/kg once a week for 8 weeks
Trial: NCT00504491
Drug: Rituximab-CHOP-Alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Four Rituximab - CHOP courses will be given The courses will be given every 21 days
Trial: NCT02261662
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.~It will be used along with Topical steroids; Betamethasone
Trial: NCT02261662
Drug: Betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical Steroids alone will be used; Betamethasone
Trial: NCT00718380
Drug: ABT-869
RxNorm normalized name: ABT-925
DrugBank: ABT-639 (DB15055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg or 10 mg tablet, Once a day, oral dose, dose per body weight (dose determined by group; 2.5mg or 10mg tablet) until evidence of uncontrolled unacceptable toxicity or disease progression. For more information, please see Arm Description.
Trial: NCT00518635
Drug: Nutropin
RxNorm normalized name: Nutropin
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutropin 0.1 mg/day self-administered once a day
Trial: NCT01328548
Drug: Zostavax
RxNorm normalized name: Zostavax
DrugBank: Varicella zoster vaccine (live/attenuated) (DB10318)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03491631
Drug: SHR9146+SHR-1210
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR9146: Initial dose of 100mg BID with escalation planned to 600mg BID; SHR-1210: 200mg Q2W
Trial: NCT03491631
Drug: SHR9146+SHR-1210+Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR9146: Initial dose of 100mg BID with escalation planned to 600mg BID; SHR-1210: 200mg Q2W Apatinib:250mg QD
Trial: NCT00351637
Drug: Sublingual Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03326960
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia maintenance with sevoflurane guided by Narcrotrend index monitoring.
Trial: NCT03326960
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia maintenance with propofol guided by Narcrotrend index monitoring.
Trial: NCT03326960
Drug: Desflurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia maintenance with desflurane guided by Narcrotrend index monitoring.
Trial: NCT03221842
Drug: C1-esterase inhibitor
RxNorm normalized name: HUMAN C1-ESTERASE INHIBITOR
DrugBank: Conestat alfa (DB09228)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: C1-esterase inhibitor is a human plasma-derived lyophilised powder for reconstitution
Trial: NCT00900731
Drug: Indacaterol 150 μg
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
Trial: NCT00900731
Drug: Tiotropium 18 μg
RxNorm normalized name: tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18 μg was provided in powder filled capsules with the manufacturer's proprietary inhalation device (HandiHaler®).
Trial: NCT00900731
Drug: Placebo to indacaterol
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
Trial: NCT00900731
Drug: Placebo to tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to tiotropium was provided in powder filled capsules with the manufacturer's proprietary inhalation device (HandiHaler®).
Trial: NCT02173990
Drug: Aflibercept-FOLFIRI
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflibercept : 4 mg/kg, IV over 1 h on Day 1~FOLFIRI :~* Irinotecan 180 mg/m² IV infusion in 500 mL D5W (5% Dextrose in Water solution) over 90 minutes and dl leucovorin\* 400 mg/m² IV infusion over 2 hours, at the same time, in bags using a Y-line, followed by :~* 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by :~* 5-FU 2400 mg/m² continuous IV infusion in 500 mL over 46-hours.~  * \*400 mg/m² of leucovorin expressed in dl racemic. When the l-isomer form is used the dose should be divided by 2, i.e. 200 mg/m²
Trial: NCT01184105
Drug: Intervention A
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of 60 mg will consist of 6 sprays of the 10 mg strength spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)
Trial: NCT00247507
Drug: acetylcysteine
RxNorm normalized name: Acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00462254
Drug: ROZEREM
RxNorm normalized name: Rozerem
DrugBank: Ramelteon (DB00980)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 mg tablet orally 30 minutes before bedtime for 8 days (Days 4-11).
Trial: NCT04106050
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT02953106
Drug: Azelastine-Fluticasone Nasal
RxNorm normalized name: azelastine-fluticasone nasal
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 137 micrograms azelastine hydrochloride / 50 micrograms fluticasone propionate
Trial: NCT00462254
Drug: Ramelteon
RxNorm normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 mg tablet orally 30 minutes before bedtime for 8 days (Days 15-22).
Trial: NCT02145325
Drug: Expanded Tregs
RxNorm normalized name: Col-Treg
DrugBank: Col-Treg (DB18451)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03996408
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a multi-target receptor tyrosine kinase inhibitor
Trial: NCT01615211
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 1 Letrozole 2,5mg 3 tablets Day 2 Letrozole 2,5mg 3 tablets
Trial: NCT01615211
Drug: Trilostane
RxNorm normalized name: TRILOSTANE
DrugBank: Trilostane (DB01108)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 1 Trilostane 120mg twice and Day 2 Trilostane 240mg twice
Trial: NCT00409695
Drug: Low Dose Thymoglobulin (ATG)
RxNorm normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg /kg by vein every other day for 3 doses (total dose = 7.5 mg/ kg).
Trial: NCT00409695
Drug: High Dose Thymoglobulin (ATG)
RxNorm normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25mg/kg by vein every other day for 3 doses (total dose = 3.75mg/kg)
Trial: NCT03195647
Drug: Potassium
RxNorm normalized name: Potassium
DrugBank: Potassium citrate (DB09125)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference.~Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol.
Trial: NCT00855205
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab will be administered by IV infusion at a dose of 1000 mg (1 g) on day 1 and 15
Trial: NCT01306045
Drug: MK-2206
RxNorm normalized name: MK-2206
DrugBank: MK-2206 (DB16828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle = 28 days MK-2206 200 mg by mouth (PO) every (Q) Week
Trial: NCT01306045
Drug: Lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cycle = 21 days Lapatinib 1500 mg by mouth (PO) every day (QD)
Trial: NCT01306045
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cycle = 21 days Erlotinib 150 mg by mouth (PO) every morning (QAM)
Trial: NCT01306045
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cycle = 42 days Sunitinib 50 mg by mouth (PO) on days 1-28
Trial: NCT04608344
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as single dose tablet orally.
Trial: NCT04608344
Drug: Filgotinib
RxNorm normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Administered as tablet orally once daily for 11 days.
Trial: NCT03191864
Drug: APT-1011
RxNorm normalized name: tetracycline
DrugBank: APT-101 (DB18003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate
Trial: NCT00534079
Drug: Dornase alfa (Pulmozyme)
RxNorm normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 2,5 ml per day, inhalation use, for 28 days
Trial: NCT03144843
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
Trial: NCT01794273
Drug: ephedrine and phenylephrine
RxNorm normalized name: Carbetapentane and chlorpheniramine and ephedrine and phenylephrine only product
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01794793
Drug: Pasireotide
RxNorm normalized name: Pasireotide
DrugBank: Pasireotide (DB06663)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously in strengths 0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines.
Trial: NCT01794793
Drug: Cabergoline
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabergoline tablet 0.5mg or 1.0mg taken by mouth once daily may be combined with subcutaneous formulation of pasireotide for Cushing's Disease or Acromegaly. Dose is dependent on parent study guidelines.
Trial: NCT01794793
Drug: Pasireotide LAR
RxNorm normalized name: pasireotide LAR 20 MG Injection
DrugBank: Pasireotide (DB06663)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long Acting Release is administered by a single intramuscular (i.m.) monthly injection. The strengths are 10mg, 20mg, 40mg and 60mg. All doses to be taken q28days. Strength is dependent on parent study guidelines.
Trial: NCT03647774
Drug: Extended release naltrexone
RxNorm normalized name: bupropion / naltrexone Extended Release Oral Tablet
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 380mg injectable extended release naltrexone every four weeks
Trial: NCT02044874
Drug: APD356-lorcaserin hydrochloride
RxNorm normalized name: Lorcaserin Hydrochloride
DrugBank: Lorcaserin (DB04871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01563367
Drug: Iron isomaltoside 1000 (Monofer®)
RxNorm normalized name: ferric carboxymaltose
DrugBank: Iron isomaltoside 1000 (DB12208)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All subjects randomised to this group will receive 1000 mg iron isomaltoside 1000 as a single dose infusion administered over 15 minutes
Trial: NCT04494763
Drug: Propanolol
RxNorm normalized name: Propanolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-selective Beta-blocker
Trial: NCT00082017
Drug: UCN-01 (7-hydroxystaurosporine)
RxNorm normalized name: 7-Hydroxystaurosporine
DrugBank: 7-Hydroxystaurosporine (DB01933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 1, Cycle 1: 45 mg/m\^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m\^2 Cycle 2: 45 mg/m\^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m\^2; Repeat cycles every 28 days.~UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 2, Cycle 1: 45 mg/m\^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m\^2 Cycle 2: 45 mg/m\^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m\^2; Repeat cycles every 21 days.
Trial: NCT04005144
Drug: Binimetinib
RxNorm normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT04005144
Drug: Brigatinib
RxNorm normalized name: Brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT01848743
Drug: Tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00084214
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00146614
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00146614
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01848743
Drug: lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00778102
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bolus 400mg/m2, day 1 every 2 weeks
Trial: NCT00778102
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3200mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
Trial: NCT00778102
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2400mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
Trial: NCT00778102
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 165mg/m2 1-hour iv infusion, day 1 every 2 weeks
Trial: NCT00778102
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85mg/m2 2-hour iv infusion, day 1 every 2 weeks
Trial: NCT00778102
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5mg/kg iv day 1 every 2 weeks
Trial: NCT03204487
Drug: Tafluprost 15µg/ml
DrugBank: Tafluprost (DB08819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tafluprost 15µg/ml (Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis, Merck Sharp \& Dohme, Wien)
Trial: NCT00779532
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules containing 400 mg moxifloxacin, on Day 14 only
Trial: NCT00779532
Drug: NOMAC-E2 (Org 10486-0 + Org 2317)
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing 2.5 mg NOMAC and 1.5 mg E2, once daily dosing, orally taken. Daily dose either NOMAC-E2 2.5/1.5 mg or 12.5/7.5 mg.
Trial: NCT00779532
Drug: Moxifloxacin placebo
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin-placebo capsule taken orally, Day -1 and Day 14 only
Trial: NCT03031574
Drug: SUVN-D4010
RxNorm normalized name: SUVN-502
DrugBank: SUVN-502 (DB06140)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT02868567
Drug: dalfampridine
RxNorm normalized name: Dalfampridine
DrugBank: Dalfampridine (DB06637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill open label
Trial: NCT00787917
Drug: Omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Omalizumab subcutaneous injections of 600 mg daily.
Trial: NCT00787917
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole twice daily with a maximum daily dose of 400 mg.
Trial: NCT01959698
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01959698
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01959698
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01959698
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV